How to apply for Executive Director, Asset Team Lead

About Recursion

Recursion is a clinical-stage biotech that uses its proprietary Recursion OS and ClinTech platform to industrialize drug discovery. The company pairs computational approaches with traditional preclinical and clinical development, and this role sits at the intersection of those two worlds. It may appeal to people who want to work on data-driven drug development rather than conventional pharma pipelines.

About the role

This executive director role leads asset strategy for small molecule clinical programs in oncology and immunology/inflammation. You will integrate competitive positioning, mechanistic differentiation, biomarker strategy, and patient segmentation to drive go/no-go and prioritization decisions. The role requires translating Recursion OS and ClinTech insights into strategic asset advantages across the portfolio.

A typical day

A typical day may involve working with preclinical, clinical, and platform teams to review asset data and sharpen go/no-go criteria. You might translate Recursion OS or ClinTech outputs into strategic recommendations, align cross-functional partners on prioritization, and prepare decision materials for portfolio reviews. The exact rhythm depends on the team and pipeline stage, so ask about meeting cadence and decision forums during interviews.

Who Recursion is looking for

• Has led asset strategy or program teams for small molecule clinical programs in oncology and/or immunology/inflammation, ideally through key inflection points such as IND, Phase 1/2, or go/no-go decisions.
• Can translate scientific and computational complexity into clear strategic choices for cross-functional partners in preclinical, clinical, and platform teams.
• Understands how to use biomarker strategy and patient segmentation to sharpen competitive positioning and prioritization.
• Has worked in or alongside data-driven or computational drug discovery environments, or can show how they would apply proprietary platform insights to asset decisions.

Tips for this application

• In your resume, name the specific small molecule assets or programs you led and the inflection points you drove, such as go/no-go decisions, biomarker strategies, or patient segmentation work.
• Use the cover letter to explain how you have translated computational or platform-derived insights into asset strategy decisions, since Recursion OS and ClinTech are central to this role.
• Address both oncology and immunology/inflammation experience if you have it; if you only have one, state how you would ramp up on the other.
• Show familiarity with Recursion's pipeline and public disclosures about its clinical assets, and reference them specifically rather than speaking about the company in general terms.
• If you have worked across functional lines with preclinical, clinical, and platform teams, give one concrete example of how you aligned those groups around a portfolio decision.

What to cover in your cover letter

['Your track record leading asset strategy for small molecule clinical programs in oncology and/or immunology/inflammation, including specific go/no-go or prioritization decisions you drove.', 'How you have used biomarker strategy, patient segmentation, and competitive positioning to sharpen asset decisions.', 'Your experience translating computational or platform-derived insights into strategic advantage, and why that matters for Recursion OS and ClinTech.', 'How you work across preclinical, clinical, and platform teams to align on portfolio goals and move with urgency.']

Research before applying

• Recursion's clinical pipeline and which small molecule assets are in oncology and immunology/inflammation, including their current phase and disclosed inflection points.
• What Recursion OS and ClinTech actually are, based on the company's public materials, and how they are described as enabling asset decisions.
• Recursion's recent public statements about portfolio prioritization, partnerships, or pipeline changes, so you can speak to the current strategic context.
• The competitive landscape for the specific indications Recursion is targeting, including standard of care and any differentiated mechanisms.

Likely interview topics

Based on the job description, expect questions about:

• How you would define and drive asset strategy for a small molecule clinical program in oncology or immunology/inflammation, from competitive positioning through go/no-go.
• A specific example of translating computational or platform insights into a strategic asset decision, and what the outcome was.
• How you approach biomarker strategy and patient segmentation to differentiate an asset in a competitive landscape.
• How you align preclinical, clinical, and platform teams when they have different priorities or timelines.
• Your view on how Recursion OS and ClinTech can change traditional drug development paradigms, and where you see the limits.

Common mistakes to avoid

• Speaking only in general terms about drug development without naming specific assets, phases, or go/no-go decisions you led.
• Ignoring the computational and platform side of the role, or treating Recursion OS and ClinTech as buzzwords rather than tools that shape asset strategy.
• Focusing only on one therapeutic area when the role spans oncology and immunology/inflammation, without addressing how you would cover both.